two years to get patent, page-7

Markfs, that is correct. It is not only the hoops you have to check. Partnership prospects are what you should be looking for in these small Biotechs in my opinion. Unless trial results are so compelling that accelerated approval(dont rule that out with SBP yet)kicks in, then it can cost hundreds of millions to get a drug to market.
The most famous example was Erbitux. Bristol Meyers paid $1 billion up front for a 20% stake of Imclones Erbitux. Imclones shares went to $70. The FDA knocked back the initial application. A few people went to jail over share trades. Erbitux was approved on a subsequent application and is now in use on head and neck cancers and others. Last month Amgen bought Abgenix for $2.2Billion. Abgenix has an osteoporosis drug that it co developed with Amgen, and Panitumumab. Panitumumab is also a monoclonal antibody like Erbitux and they say will likely be strong competition. In trials it reduced tumour progression in 46% of patients. It dosnt matter if you dont take the drug all the way to market, if you have a best in class drug it could blow the SP through the roof in a small market cap company like SBP with a partnership deal in my opinion.
The newest director in SBP was doing new drug developement for Pfizer as I recall.Check on the SBP announcements. Pfizer is one of the worlds biggest Pharmas.
Solbec has seen a durable 80% response on an advanced refractory renal cell carcinoma patient.There is nothing on the market capable of anything like that if it if they can reliably repeat this in the Phase 2. The phase 2, starting shortly, will likely be against earlier stage cancers with an even better chance of success.
All the above is to the best of my knowledge, so do your own research. Good luck.